leisure time
Previous article:
Duchenne breakthrough therapy leaves behind pioneering families
Next article: Abbott's new heart device gets FDA advisory panel nod
Next article: Abbott's new heart device gets FDA advisory panel nod
hotspot
hotspot
-
Coloradans with cystic fibrosis could lose access to Trikafta
2025-09-30 17:35 -
Life sciences investors close nearly $6 billion in new funds
2025-09-30 16:32 -
Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline
2025-09-30 16:07 -
After Sarepta trial failure, Duchenne families brace for more debate
2025-09-30 15:43 -
The health care issue Democrats can’t solve: hospital reform
2025-09-30 15:35 -
All of Us, NIH's precision medicine initiative, gets a big boost
2025-09-30 15:16